SCHEMBL3148226

SCHEMBL3148226

CN(C(=O)CN1CCN(C(=O)c2ccc(S(=O)(=O)Nc3ccccc3Oc3ccc(Cl)c(Cl)c3)cc2)CC1)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
GAA P10253 1/20 0.47
PKM P14618 1/20 0.47
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
KMT2A Q03164 2/20 0.44
HCRTR1 O43613 1/20 0.44
RAB9A P51151 1/20 0.43
CCR2 P41597 2/20 0.43
CCR1 P32246 1/20 0.43
CCR5 P51681 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
CACNA1H O95180 1/20 0.42
CACNA1B Q00975 1/20 0.42
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153746 0.88 F10 (0.45) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3153822 0.87 ALDH1A1 (0.47) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3149459 0.86 L3MBTL1 (0.49) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL15016254 0.85 CACNA1H (0.50) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3149140 0.85 L3MBTL1 (0.50) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3157725 0.85 CCR2 (0.55) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3153568 0.84 CCR2 (0.57) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3143378 0.84 ALDH1A1 (0.46) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3148911 0.84 ALDH1A1 (0.44) ALDH1A1GAAPKMMAPK1SMN1; SMN2
SCHEMBL3153219 0.83 KMT2A (0.51) ALDH1A1GAAPKMMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074083-B1 NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT (HU) 2013-06-19 EP disclosed
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS RICHTER GEDEON NYRT. (HU) 2010-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075978-A1 SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS BDKRB1, BDKRB2, TRPV1 ALDH1A1 3552/4885GAA 4410/4885PKM 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.